Phenotype plasticity as enabler of melanoma progression and therapy resistance
AffiliationNavarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Publica de Navarra (UPNA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain
MetadataShow full item record
AbstractMalignant melanoma is notorious for its inter- and intratumour heterogeneity, based on transcriptionally distinct melanoma cell phenotypes. It is thought that these distinct phenotypes are plastic in nature and that their transcriptional reprogramming enables heterogeneous tumours both to undergo different stages of melanoma progression and to adjust to drug exposure during treatment. Recent advances in genomic technologies and the rapidly expanding availability of large gene expression datasets have allowed for a refined definition of the gene signatures that characterize these phenotypes and have revealed that phenotype plasticity plays a major role in the resistance to both targeted therapy and immunotherapy. In this Review we discuss the definition of melanoma phenotypes through particular transcriptional states and reveal the prognostic relevance of the related gene expression signatures. We review how the establishment of phenotypes is controlled and which roles phenotype plasticity plays in melanoma development and therapy. Because phenotype plasticity in melanoma bears a great resemblance to epithelial-mesenchymal transition, the lessons learned from melanoma will also benefit our understanding of other cancer types.
CitationArozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019 Jul;19(7):377-91.
JournalNature Reviews. Cancer
- Cooperative behaviour and phenotype plasticity evolve during melanoma progression.
- Authors: Rowling EJ, Miskolczi Z, Nagaraju R, Wilcock DJ, Wang P, Telfer B, Li Y, Lasheras-Otero I, Redondo-Muñoz M, Sharrocks AD, Arozarena I, Wellbrock C
- Issue date: 2020 Sep
- Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression.
- Authors: Pessoa DO, Rius FE, Papaiz DD, Ayub ALP, Morais AS, de Souza CF, da Paixão VF, Setubal JC, Newton-Bishop J, Nsengimana J, Azevedo H, Reis EM, Jasiulionis MG
- Issue date: 2021 Apr
- Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
- Authors: Roesch A, Paschen A, Landsberg J, Helfrich I, Becker JC, Schadendorf D
- Issue date: 2016 May
- Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
- Authors: Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, Siddaway R, Lisle R, Freter R, Daniels MJ, Lu X, Tüting T, Middleton M, Buffa FM, Willis AE, Pavitt G, Ronai ZA, Sauka-Spengler T, Hölzel M, Goding CR
- Issue date: 2017 Jan 1
- Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
- Authors: Castro-Pérez E, Rodríguez CI, Mikheil D, Siddique S, McCarthy A, Newton MA, Setaluri V
- Issue date: 2019 Jul 9